Phase III Comparison of High-Dose Paclitaxel + Cisplatin + Granulocyte Colony-Stimulating Factor Versus Low-Dose Paclitaxel + Cisplatin in Advanced Head and Neck Cancer: Eastern Cooperative Oncology Group Study E1393

Forastiere, Arlene A.; Leong, Traci; Rowinsky, Eric K.; Murphy, Barbara A.; Vlock, Daniel R.; DeConti, Ronald C.; Adams, George L.

doi:10.1200/jco.2001.19.4.1088

Cited by 151 publications

(76 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although cisplatin is a potent and widely used anticancer drug, in solid tumors, its clinical use is often limited by hematologic toxicity, nephrotoxicity, myelosuppression as well as other complications, such as cardiovascular consitions and hearing loss (16,17). The group of taxanes is also highly active in head and neck cancer disease.…”

Section: Discussionmentioning

confidence: 99%

Antitumoral effect of PLK-1-inhibitor BI2536 in combination with cisplatin and docetaxel in squamous cell carcinoma cell lines of the head and neck

Wagenblast

Hirth

Eckardt

et al. 2012

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Inhibition of the polo-like-kinase-1 (PLK-1) has been shown to be effective in several haematological and solid tumor models. In this systemic in vitro study, the antitumor effect of BI2536, a small molecule inhibitor of PLK-1, in combination with cisplatin and docetaxel was examined in nine squamous cell carcinoma cell lines, most of which had a head and neck origin (SCCHN). Dose escalation studies were conducted with nine SCCHN cell lines using BI2536, cisplatin and docetaxel in cell line-specific concentrations. Growth inhibitory and proapoptotic effects were measured quantitatively using cytohistology and a Human Apoptose Array kit. BI2536 in combination with cisplatin and docetaxel showed a markedly higher antiproliferative and apoptotic activity in the SCCHN cell lines investigated (P≤0.008), compared with single agent cisplatin or docetaxel alone. The findings of this study showed that the addition of PLK-1-inhibitor BI2536 to conventional chemotherapeutic drugs led to a statistically higher antiproliferative and apoptotic effect in SCCHN cell lines compared with cisplatin or docetaxel alone. Inaugurating BI2536 in the clinical setting might enhance the antitumoral activity of conventional drugs, possibly leading to less toxic side effects of cancer therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Antitumoral effect of PLK-1-inhibitor BI2536 in combination with cisplatin and docetaxel in squamous cell carcinoma cell lines of the head and neck

Wagenblast

Hirth

Eckardt

et al. 2012

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Multi-agent chemotherapy regimens may have a response rate of up to 35 %, but results are rarely durable and long-term survival is rare [42]. In these patients, re-irradiation, if applicable,…”

Section: Surgical Salvage Approachesmentioning

confidence: 99%

Salvage surgery for head and neck squamous cell carcinoma

Mandapathil

Roessler

Werner

et al. 2014

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

“…[62][63][64][65][66] For patients with excellent performance status, normal end-organ function, and no significant comorbidities, combination chemotherapy regimens are recommended. Most frequently used are two-drug combination regimens (cisplatin þ 5-FU, 67,68 cisplatin þ paclitaxel, 69,70 cisplatin þ docetaxel, [71][72][73][74] carboplatin þ taxane [75][76][77] ) and are associated with improved response rates compared with single agent, but they are also associated with increased toxicity and no statistically significant survival benefit.…”

Section: Chemotherapy In Metastatic Diseasementioning

confidence: 99%

The Role of Chemotherapy in the Management of Patients with Head and Neck Cancer

Savvides

2010

Seminars in Plastic Surgery

View full text Add to dashboard Cite

Recent advances in the management of patients with head and neck cancer point to an expanding role of chemotherapy, resulting in an increased involvement of the medical oncologist in the multidisciplinary care of these patients. This review focuses on patients with squamous cell carcinoma of the oral cavity, pharynx, and larynx. A comprehensive review of the clinical trial data that have defined new standards of care and a detailed presentation of widely used chemotherapeutic regimens, including both cytotoxic and molecularly targeted agents, are presented. Information on human papilloma virusassociated squamous cell cancer of the head and neck is presented, and implications in the clinical management of this subgroup of patients based on the epidemiologic and pathologic characteristics are discussed.KEYWORDS: Cancer of the head and neck, chemotherapy, squamous cell carcinoma Approximately 48,000 new cases of head and neck cancer were expected in the United States in 2009 alone, 1 and more than 600,000 new cases will be diagnosed worldwide. Head and neck cancer accounts for 3 to 4% of all cancer diagnoses in Western countries, 2,3 and its incidence is higher in southeast Asia and in Africa where it accounts for 8 to 10% of all cancers. 4 Overall, head and neck cancer represents the eighth most common cause of cancer death.Historically, treatment of patients with squamous cell carcinoma of the head and neck (SSCHN) has primarily been driven by surgical interventions and continued advances in radiation therapy (RT) treatment planning and delivery. In this setting of complex treatment algorithms, recent advances in the management of patients with head and neck cancer point to an expanding role of chemotherapy and therefore an increased involvement of the medical oncologist in the multidisciplinary care of these patients.The scope of this review is to provide a comprehensive description of expanding chemotherapeutic options, including both cytotoxic and molecularly targeted agents, that are applicable to patients diagnosed with squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx. Data on patients diagnosed with cancer of the nasopharynx will be presented separately because of its distinct etiology, pathology, and response to treatment modalities.Chemotherapy alone does not have curative potential. As a result, it does not have a defined role

show abstract

Phase III Comparison of High-Dose Paclitaxel + Cisplatin + Granulocyte Colony-Stimulating Factor Versus Low-Dose Paclitaxel + Cisplatin in Advanced Head and Neck Cancer: Eastern Cooperative Oncology Group Study E1393

Abstract: This phase III multicenter trial showed (1) no advantage for high-dose paclitaxel and (2) excessive hematologic toxicity associated with both regimens. Therefore, neither of the paclitaxel regimens evaluated in this trial can be recommended.

Cited by 151 publications

References 10 publications

Antitumoral effect of PLK-1-inhibitor BI2536 in combination with cisplatin and docetaxel in squamous cell carcinoma cell lines of the head and neck

Antitumoral effect of PLK-1-inhibitor BI2536 in combination with cisplatin and docetaxel in squamous cell carcinoma cell lines of the head and neck

Salvage surgery for head and neck squamous cell carcinoma

The Role of Chemotherapy in the Management of Patients with Head and Neck Cancer

Contact Info

Product

Resources

About